Vaxcyte (PCVX) Treasury Shares (2019 - 2026)

Vaxcyte (PCVX) posted quarterly Treasury Shares of $3.3 million for Q1 2026, up 42.27% quarter-over-quarter from $2.3 million in Q4 2025.

Vaxcyte (PCVX) Treasury Shares (2019 - 2026) Analysis & Trends

Vaxcyte (PCVX) has reported Treasury Shares for 7 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

In Q1 2026, Treasury Shares changed N/A year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (changed N/A YoY), while the FY2025 annual figure was $2.3 million, up 1233.57% from the prior year.
Treasury Shares rose to $3.3 million in Q1 2026 per PCVX's latest filing, from $2.3 million in the prior quarter.
Across five years, Treasury Shares topped out at $3.3 million in Q1 2026 and bottomed at $175513.0 in Q1 2024.
Historically, Treasury Shares has averaged $1.0 million across 5 years, with a median of $726940.0 in 2023.
Annual changes were most pronounced in 2024 — Treasury Shares plunged 77.99% — and 2025, when it soared 1233.57%.
Vaxcyte's Treasury Shares stood at $456766.0 in 2022, then jumped by 64.96% to $753462.0 in 2023, then slumped by 76.71% to $175513.0 in 2024, then jumped by 1233.57% to $2.3 million in 2025, then jumped by 42.27% to $3.3 million in 2026.
Business Quant data shows PCVX's Treasury Shares at $3.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	5.08 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	2.72 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	92,219.00
10	Vaxcyte	8.41 Bn	8.41 Bn	-	3.22 Mn

Download Data